Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 3/20 | 0.58 |
| ▸ | GRM5 | P41594 | 5/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 1/20 | 0.32 |
| ▸ | FDPS | P14324 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20201429 | 1.00 | ENO1 (0.58) | ENO1GRM5NAMPTBRD4BRD2 | |
| SCHEMBL20201424 | 0.94 | ENO1 (0.65) | ENO1GRM5BRD4BRD2DPP4 | |
| SCHEMBL20201431 | 0.94 | ENO1 (0.65) | ENO1GRM5BRD4BRD2DPP4 | |
| SCHEMBL20201428 | 0.86 | ENO1 (0.62) | ENO1DPP4 | |
| SCHEMBL20201419 | 0.86 | ENO1 (0.62) | ENO1DPP4 | |
| SCHEMBL18077428 | 0.79 | ENO1 (0.89) | ENO1DPP4 | |
| SCHEMBL18077430 | 0.79 | ENO1 (0.89) | ENO1DPP4 | |
| SCHEMBL18077425 | 0.73 | ENO1 (1.00) | ENO1DPP4 | |
| SCHEMBL19345925 | 0.72 | BRD4 (0.38) | GRM5NAMPTBRD4BRD2HTR5A | |
| SCHEMBL13502662 | 0.70 | CA1 (0.43) | GRM5BRD4BRD2HTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180147219-A1 | ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180147219-A1 | ENOLASE INHIBITORS AND METHODS OF TREATMENT THEREWITH | ENO1, ECE1, ECI1 | ENO1 1/4885GRM5 4052/4885NAMPT 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.